STOCK TITAN

Summit Therapeutics co-CEO exercises 300K-share option

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Summit Therapeutics Inc. co-CEO Mahkam Zanganeh exercised an option for 300,000 common shares at $1.06 per share on November 20, 2026. Her direct common-stock holdings after the exercise were 831,000 shares, and the reported option balance was 500,000.

Indirect holdings reported after the transaction were 25,824,474 shares in the Mahkam Zanganeh Revocable Trust, 76,680 held by an immediate family member, 10,199,776 in the Shaun Zanganeh Irrevocable Trust and 573,883,879 held by her spouse. Zanganeh disclaimed beneficial ownership of the reported securities except to the extent of her pecuniary interest.

Insider Zanganeh Mahkam
Role Co-Chief Executive Officer
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1, F3 300,000 $0.00 $0.00
Exercise Common Stock F1 300,000 $1.06 $318K
Holding Common Stock F2 -- -- --
Holding Common Stock F2 -- -- --
Holding Common Stock F2 -- -- --
Holding Common Stock F2 -- -- --
Holdings After Transaction: Stock Option (right to buy) — 500,000 options (Direct); Common Stock — 831,000 shares (Direct); Common Stock — 25,824,474 shares (Indirect, By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee); Common Stock — 76,680 shares (Indirect, Immediate family member); Common Stock — 10,199,776 shares (Indirect, By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee); Common Stock — 573,883,879 shares (Indirect, By Spouse)
Footnotes (3)
  1. F1. On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.
  2. F2. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  3. F3. The option was granted on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.
Common shares acquired 300,000 shares Option exercise on November 20, 2026
Exercise price $1.06 per share Option exercised on November 20, 2026
Direct common shares 831,000 shares Reported following the exercise
Options 500,000 options Reported following the exercise
Mahkam Zanganeh Revocable Trust common shares 25,824,474 shares Indirect holding reported after the transaction; Zanganeh disclaimed beneficial ownership except to the extent of her pecuniary interest
Immediate family member common shares 76,680 shares Indirect holding reported after the transaction; Zanganeh disclaimed beneficial ownership except to the extent of her pecuniary interest
Shaun Zanganeh Irrevocable Trust common shares 10,199,776 shares Indirect holding reported after the transaction; Zanganeh disclaimed beneficial ownership except to the extent of her pecuniary interest
Spouse common shares 573,883,879 shares Indirect holding reported after the transaction; Zanganeh disclaimed beneficial ownership except to the extent of her pecuniary interest
pecuniary interest financial
"except to the extent of her pecuniary interest therein"
performance criteria technical
"based on satisfaction of certain performance criteria"
service-based vesting requirements technical
"require only the service-based vesting requirements to continue to be satisfied"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Summit Therapeutics (SMMT) co-CEO Mahkam Zanganeh acquire through the option exercise?

She acquired 300,000 common shares by exercising an option on November 20, 2026, at $1.06 per share. Her reported direct common-stock holdings after the transaction were 831,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Zanganeh Mahkam

(Last)(First)(Middle)
C/O SUMMIT THERAPEUTICS INC.
601 BRICKELL KEY DRIVE, SUITE 1000

(Street)
MIAMI FLORIDA 33131

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Co-Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/20/2026M(1)300,000A$1.06831,000D
Common Stock25,824,474(2)IBy the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee
Common Stock76,680(2)IImmediate family member
Common Stock10,199,776(2)IBy the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee
Common Stock573,883,879(2)IBy Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.0611/20/2026M(1)300,000 (3)06/28/2032Common Stock300,000$0500,000D
Explanation of Responses:
1. On November 20, 2026, the Reporting Person exercised an option to purchase 300,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.
2. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
3. The option was granted on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.
Remarks:
/s/ Mahkam Zanganeh11/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading